SEATTLE–(BUSINESS WIRE)– LumiThera kondigt start aan van EUROLIGHT-registeronderzoek om langetermijnvoordelen van fotobiomodulatie (PBM)-behandeling met behulp van het Valeda® Light Delivery System te evalueren bij patiënten met droge leeftijdsgebon…
Category: Business
LumiThera kündigt den Beginn der EUROLIGHT-Registerstudie an, um die langfristigen Vorteile der Photobiomodulationsbehandlung (PBM) mit dem Valeda® Light Delivery System bei Patienten mit trockener altersbedingter Makuladegeneration (AMD) zu…
SEATTLE–(BUSINESS WIRE)– LumiThera kündigt den Beginn der EUROLIGHT-Registerstudie an, um die langfristigen Vorteile der Photobiomodulationsbehandlung (PBM) mit dem Valeda® Light Delivery System bei Patienten mit trockener altersbedingter Makuladege…
LumiThera anuncia el inicio del estudio de registro EUROLIGHT para evaluar los beneficios a largo plazo del tratamiento de fotobiomodulación (PBM, por sus siglas en inglés) utilizando el Valeda® Light Delivery System en pacientes con degeneración…
SEATTLE–(BUSINESS WIRE)– LumiThera anuncia el inicio del estudio de registro EUROLIGHT para evaluar los beneficios a largo plazo del tratamiento de fotobiomodulación (PBM, por sus siglas en inglés) utilizando el Valeda® Light Delivery System en paci…
Aviceda Therapeutics gibt Topline-Daten von Teil 1 der klinischen Phase-2/3-SIGLEC-Studie für AVD-104 bekannt, die eine positive Sicherheitsbewertung und eine frühe klinische Wirksamkeit bei Patienten mit geografischer Atrophie belegen
CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Aviceda Therapeutics, ein im klinischen Stadium tätiges Biotech-Unternehmen, dessen Schwerpunkt auf der Entwicklung neuartiger Glyko-Immuntherapeutika liegt, die das körpereigene Immunsystem zur Modulation von…
RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced t…
LumiThera Announces Initiation of EUROLIGHT Registry Study to Evaluate Long-term Benefits of Photobiomodulation (PBM) Treatment using the Valeda® Light Delivery System in Patients with Dry Age-Related Macular Degeneration (AMD)
SEATTLE–(BUSINESS WIRE)– #DryAMD–LumiThera Initiates EUROLIGHT Registry Study to Evaluate Long-term Benefits of Valeda® Treatments in Dry Age-Related Macular Degeneration Patients.
Aviceda Therapeutics Announces Topline Data from Part 1 of the Phase 2/3 SIGLEC Clinical Trial for AVD-104, Demonstrating Positive Safety and Early Clinical Efficacy in Patients with Geographic Atrophy
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics, a clinical-stage biotech company focused on developing novel glyco-immune therapeutics by harnessing the body’s natural immune system to modulate inflammation by using highly selective ligands de…
Nordic Group B.V., par l'intermédiaire de sa filiale Amring Pharmaceuticals Inc. annonce la nomination de Jai G. Parekh, MD, MBA, au poste de directeur commercial d’Eye Care U.S.
BERWYN, Pennsylvanie–(BUSINESS WIRE)–Amring Pharmaceuticals Inc. (Amring), filiale de Nordic Group B.V. (Nordic Pharma), annonce la nomination de Jai G. Parekh, MD, MBA au poste de directeur commercial chez Eye Care U.S. Nordic Pharma a récemment dév…
Riassunto: Nordic Group B.V. annuncia tramite la sua affiliata Amring Pharmaceuticals Inc. la nomina del dott. Jai G. Parekh, MBA, come Direttore commerciale di Eye Care negli USA
BERWYN, Pennsylvania (USA)–(BUSINESS WIRE)–Amring Pharmaceuticals Inc. (Amring), società affiliata di Nordic Group B.V. (Nordic Pharma), ha annunciato la nomina del dott. Jai G. Parekh, MBA, in qualità di Direttore commerciale di Eye Care negli USA. …
Nordic Group B.V. gibt über ihre Tochtergesellschaft Amring Pharmaceuticals Inc. die Ernennung von Jai G. Parekh, MD, MBA zum Chief Commercial Officer, Eye Care U.S. bekannt
BERWYN, Pa.–(BUSINESS WIRE)–Amring Pharmaceuticals Inc. (Amring), eine Tochtergesellschaft der Nordic Group B.V. (Nordic Pharma), gibt bekannt, dass Jai G. Parekh, MD, MBA, Chief Commercial Officer von Eye Care U.S. wird Nordic Pharma hat vor kurzem …
Samenvatting: Nordic Group B.V. kondigt via haar dochteronderneming Amring Pharmaceuticals Inc. de benoeming aan van Jai G. Parekh, MD, MBA, als Chief Commercial Officer, Eye Care V.S.
BERWYN, Pa.–(BUSINESS WIRE)–Amring Pharmaceuticals Inc. (Amring), een dochteronderneming van Nordic Group B.V. (Nordic Pharma), kondigt aan dat Jai G. Parekh, MD, MBA, Chief Commercial Officer, Eye Care V.S. wordt. Nordic Pharma heeft onlangs zijn fa…
Resumen: Nordic Group B.V., a través de su filial Amring Pharmaceuticals Inc., anuncia el nombramiento del Dr. Jai G. Parekh como director comercial para el cuidado ocular en EE. UU.
BERWYN, Pa.–(BUSINESS WIRE)–Amring Pharmaceuticals Inc. (Amring), filial de Nordic Group B.V. (Nordic Pharma), anuncia el nombramiento del Dr. Jai G. Parekh como director comercial para el cuidado ocular en EE. UU. Nordic Pharma ha expandido reciente…
Nordic Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Announces Jai G. Parekh, MD, MBA as Chief Commercial Officer, Eye Care U.S.
BERWYN, Pa.–(BUSINESS WIRE)–Amring, a subsidiary of Nordic Group B.V. (Nordic Pharma), announces Jai G. Parekh, MD, MBA as Chief Commercial Officer, Eye Care U.S.
Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye
GENEVA–(BUSINESS WIRE)–Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye
Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye
GENEVA–(BUSINESS WIRE)–Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye
Aviceda Announces First Patient Enrolled in Phase 2 GLYCO Clinical Trial Evaluating AVD-104 for the Treatment of Diabetic Macular Edema
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics, a private clinical-stage biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to alleviate chronic, non-resolving inflammation, announced…
Zenni Optical Eyes Blazing Fast Search with Algolia
SAN FRANCISCO–(BUSINESS WIRE)–Zenni sees 34% increase in revenue with Algolia.
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced advancement of its RA…
LumiThera geeft update over FDA-beoordeling van Valeda-behandeling voor patiënten met droge AMD
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., een bedrijf gespecialiseerd in medische apparatuur dat PBM-behandeling (fotobiomodulatie) aanbiedt voor oogschade en oogaandoeningen, maakte vandaag een update bekend over de wettelijke status van het Valeda® L…
LumiThera gibt aktuellen Stand der FDA-Prüfung der Valeda-Behandlung für Patienten mit trockener AMD bekannt
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., ein Medizintechnikunternehmen, das Photobiomodulation (PBM) zur Behandlung von Augenschäden und -erkrankungen anbietet, gab heute ein Update zum Zulassungsstatus des Valeda® Light Delivery System bekannt. Nach …